Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ay 22 989
2. Ay 22-989
3. Ay 22989
4. I 2190a
5. I-2190a
6. I2190a
7. Rapamune
8. Rapamycin
1. (-)-rapamycin
2. 53123-88-9
3. Ay 22989
4. Ay-22989
5. I 2190a
6. I-2190a
7. I2190a
8. Nsc 226080
9. Rapa
10. Rapammune
11. Rapamune
12. Rapamycin
13. Siia 9268a
14. Wy 090217
15. Rapamycin (sirolimus)
16. Rapalimus
17. Wy-090217
18. L04aa10
19. Npc-12g
20. Antibiotic Ay 22989
21. Chebi:9168
22. W36zg6ft64
23. Sm-88 Component Sirolimus
24. De-109
25. Mfcd00867594
26. Nsc-226080
27. Ncgc00021305-05
28. Dsstox_cid_3582
29. Sirolimusum
30. Dsstox_rid_77091
31. Dsstox_gsid_23582
32. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,27-dihydroxy-3-{(2r)-1-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3h-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4h,6h,31h)-pentone
33. Sila 9268a
34. Supralimus
35. Rapamycin/sirolimus
36. (1r,9s,12s,15r,16e,18r,19r,21r,23s,24e,26e,28e,30s,32s,35r)-1,18-dihydroxy-12-{(2s)-1-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
37. Cas-53123-88-9
38. Perceiva
39. Cypher
40. Ccris 9024
41. Nsc226080
42. Hsdb 7284
43. 1fkb
44. 1pbk
45. Ncgc00181146-01
46. Lcp-siro
47. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1r)-2-((1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4h,6h,31h)-pentone
48. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1r)-2-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3h-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4h,6h,31h)-pentone
49. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,27-dihydroxy-3-{(1r)-2-[(1s,3r,4r)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3h-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6h,31h)-pentone
50. Rap
51. Fyarro
52. Hyftor
53. S1039
54. Sirolimus [inn]
55. Sirolimus [jan]
56. Rapamycin [mi]
57. Sirolimus [hsdb]
58. Sirolimus [usan]
59. Sirolimus [vandf]
60. Biomolki2_000084
61. Sirolimus [mart.]
62. Rapamycin C-7, Analog 4
63. Schembl3463
64. Sirolimus [usp-rs]
65. Sirolimus [who-dd]
66. Rapamycin,sirolimus,rapamune
67. Unii-w36zg6ft64
68. Bidd:pxr0165
69. Sirolimus [ema Epar]
70. Mls006010168
71. Sirolimus [usan:inn:ban]
72. Gtpl6031
73. Sirolimus [orange Book]
74. Dtxsid5023582
75. Bdbm36609
76. Ms-r001
77. Rapa, Rapamune, Sirolimus, Rpm
78. Hms2089a21
79. Hms3403f11
80. Hms3884c03
81. Ex-a1044
82. Rpm
83. Tox21_110870
84. Tox21_112750
85. Ac-722
86. Bdbm50064359
87. Stl570275
88. Akos015850976
89. Akos015961618
90. Zinc169289388
91. Ccg-100684
92. Cs-0063
93. Db00877
94. Nab-rapamycin Component Rapamycin
95. Nsc-2260804
96. Ncgc00021305-06
97. Ncgc00021305-07
98. Rapamycin From Streptomyces Hygroscopicus
99. As-11687
100. Hy-10219
101. Smr004701276
102. Fyarro (sirolimus Albumin-bound Particles)
103. Everolimus Impurity A [ep Impurity]
104. Unm-0000358684
105. A-275
106. R0097
107. Rapamycin, Vetranal(tm), Analytical Standard
108. Ec 610-965-5
109. M02444
110. Q32089
111. 123r889
112. Q-201659
113. Brd-k84937637-001-04-0
114. Brd-k84937637-001-06-5
115. Brd-k89626439-001-01-0
116. 24,25,26,27,32,33,34,34a-hexadecahydro-3h-23,27-epoxypy
117. Rapamycin From Streptomyces Hygroscopicus, >=95% (hplc), Powder
118. Rapamycin From Streptomyces Hygroscopicus, Vetec(tm) Reagent Grade, >=95%
119. Sirolimus Solution, 1.0 Mg/ml In Acetonitrile, Ampule Of 1 Ml, Certified Reference Material
120. (1r,9s,12s,15r,16e,18r,19r,21r,23s,24e,26e,28e,30s,32s,35r)-1,18-dihydroxy-12-{(2s)-1-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
121. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34 As)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hex Adecahydro-9,27-dihydroxy-3-[(1r)-2-[(1s,3r,4r)-4-hydro Xy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy- 6,8,12,14,20,26-hexamethyl-23,27-ep
122. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-9,27-dihydroxy-3-[(1r)-2-[(1s,3,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-223,27-epoxy-3h-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(6h,31h)-pentone
123. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,27-dihydroxy-3-{(1r)-2-[(1s,3r,4r)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro
124. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,27-dihydroxy-3-{(1r)-2-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3h-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4h,6h,31h)-pentone
125. (3s,6r,7e,9r,10r,12r,14s,15e,17e,19e,21s,23s,26r,27r,34as)-9,27-dihydroxy-3-{1-[(1s,3r,4r)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,
126. 1,18-dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-ethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0*4,9*]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (rapamycin)
1. (rs)-rapamycin
Molecular Weight | 914.2 g/mol |
---|---|
Molecular Formula | C51H79NO13 |
XLogP3 | 6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 6 |
Exact Mass | 913.55514157 g/mol |
Monoisotopic Mass | 913.55514157 g/mol |
Topological Polar Surface Area | 195 Ų |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 1760 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Rapamune |
PubMed Health | Sirolimus (By mouth) |
Drug Classes | Immune Suppressant |
Drug Label | Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. The chemical name of sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10... |
Active Ingredient | Sirolimus |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 1mg/ml; 0.5mg; 1mg; 2mg |
Market Status | Prescription |
Company | Pf Prism Cv |
2 of 4 | |
---|---|
Drug Name | Sirolimus |
PubMed Health | Sirolimus (By mouth) |
Drug Classes | Immune Suppressant |
Drug Label | Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. The chemical name of sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10... |
Active Ingredient | Sirolimus |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 0.5mg; 1mg; 2mg |
Market Status | Tentative Approval; Prescription |
Company | Zydus Pharms Usa; Dr Reddys Labs |
3 of 4 | |
---|---|
Drug Name | Rapamune |
PubMed Health | Sirolimus (By mouth) |
Drug Classes | Immune Suppressant |
Drug Label | Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. The chemical name of sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10... |
Active Ingredient | Sirolimus |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 1mg/ml; 0.5mg; 1mg; 2mg |
Market Status | Prescription |
Company | Pf Prism Cv |
4 of 4 | |
---|---|
Drug Name | Sirolimus |
PubMed Health | Sirolimus (By mouth) |
Drug Classes | Immune Suppressant |
Drug Label | Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. The chemical name of sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10... |
Active Ingredient | Sirolimus |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 0.5mg; 1mg; 2mg |
Market Status | Tentative Approval; Prescription |
Company | Zydus Pharms Usa; Dr Reddys Labs |
Sirolimus is indicated for the prevention of rejection of transplanted kidney allografts. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2546
Long-term results after percutaneous coronary intervention in the treatment of chronic total coronary occlusions is hindered by a significant rate of restenosis and reocclusion. In the treatment of relatively simple nonocclusive lesions, sirolimus-eluting stents have shown dramatically reduced restenosis rates compared with bare metal stents, but whether these results are more widely applicable is unknown. ... The use of sirolimus-eluting stents in the treatment of chronic total coronary occlusions is associated with a reduction in the rate of major adverse cardiac events and restenosis compared with bare metal stents.
PMID:15172397 Hoye A et al; J Am Coll Cardiol 43 (11): 1954-8 (2004)
Chronic renal failure triggered by calcineurin inhibitor (CNI)-based immunosuppression is a common complication after cardiac transplantation. Sirolimus and mycophenolate mofetil (MMF) are 2 newer immunosuppressive agents with no documented nephrotoxic side effects. This case report describes a patient with ongoing chronic renal failure 10 months after cardiac transplantation on cyclosporine-based immunosuppressive therapy. Conversion of the immunosuppressive regimen from cyclosporine to sirolimus and MMF resulted in freedom from acute rejection, excellent cardiac graft function and consistently improved renal function. This case illustrates the beneficial potential of sirolimus and MMF as CNI-free and safe long-term immunosuppression in a patient with chronic renal failure after heart transplantation.
PMID:15366440 Groetzner J et al; J Heart Lung Transplant 23 (6): 770-3 (2004)
/BOXED WARNING/ IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS. Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use Rapamune. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. The safety and efficacy of Rapamune (sirolimus) as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended. Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT): The use of Rapamune in combination with tacrolimus was associated with excess mortality and graft loss in a study in de novo liver transplant patients. Many of these patients had evidence of infection at or near the time of death. In this and another study in de novo liver transplant patients, the use of Rapamune in combination with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation and most led to graft loss or death. Lung Transplantation - Bronchial Anastomotic Dehiscence: Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when Rapamune has been used as part of an immunosuppressive regimen.
US Natl Inst Health; DailyMed. Current Medication Information for Rapamune (sirolimus) solution; Rapamune (sirolimus) tablet, sugar coated (Updated: March 2015). Available from, as of April 23, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc
Grapefruit juice may inhibit CYP 3A4 enzymes, leading to decreased metabolism of sirolimus; must not be taken with or used to dilute sirolimus.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2547
Cases of bronchial anastomotic dehiscence, most of which were fatal, have been reported in de novo lung transplant patients who received sirolimus in combination with other immunosuppressants. Because safety and efficacy of sirolimus as immunosuppressive therapy in lung transplant patients have not been established, such use in not recommended by the manufacturer.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3645
Use of sirolimus in combination with other immunosuppressants (i.e., cyclosporine, tacrolimus) has been associated with an increased risk on hepatic artery thrombosis, graft loss, and death in de novo liver transplant recipients. Because safety and efficacy of sirolimus as immunosuppressive therapy in liver transplant patients have not been established, such use is not recommended by the manufacturer.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3646
For more Drug Warnings (Complete) data for SIROLIMUS (27 total), please visit the HSDB record page.
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with [cyclosporine] and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level > 80%]), it is recommended that sirolimus be used in combination with cyclosporine and corticosteroids for the first year following transplantation. It is also used to treat lymphangioleiomyomatosis. In the US, albumin-bound sirolimus for intravenous injection is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). In Europe, it is recommended that sirolimus for the prophylaxis of organ rejection in renal transplants is used in combination with cyclosporin microemulsion and corticosteroids for two to three months. Sirolimus may be continued as maintenance therapy with corticosteroids only if cyclosporin microemulsion can be progressively discontinued.
FDA Label
Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued.
Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.
Prevention of arteriovenous access dysfunction
Treatment of chronic non-infectious uveitis
Sirolimus is an immunosuppressant drug with antifungal and antitumour effects. In animal models, sirolimus prolonged allograft survival following various organ transplants and reversed an acute rejection of heart and kidney allografts in rats. Upon oral administration of 2 mg/day and 5 mg/day, sirolimus significantly reduced the incidence of organ rejection in low- to moderate-immunologic risk renal transplant patients at six months following transplantation compared with either azathioprine or placebo. In some studies, the immunosuppressive effect of sirolimus lasted up to six months